⚡️ Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies

#BladderCancer Francesco Ditonno Alessandro Antonelli Simone Crivellaro OncoAlert

bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj…

LBA4517: Andrea Necchi
Perioperative sacituzumab govitecan (SG) alone or in combination with pembrolizumab (Pembro) for patients with muscle-invasive urothelial bladder cancer (MIBC): SURE-01/02 interim results.
I am eagerly anticipating the results of this study, which reports

Abstract #4502 Shilpa Gupta
⭕️In the EV-302 trial, EV+P nearly doubled median progression-free and overall survival!
⭕️ PROs showed better pain reduction and maintained QoL with EV+P. This supports EV+P's value for these patients. #ASCO24 #BladderCancer
Omar Abdihamid, Oncologist ASCO FCOI: bit.ly/3KkgH Jacob J. Adashek, DO

This study will be presented at #ASCO24 !

Shilpa Gupta & cols found that many Eu5 physicians set age thresholds for 1L systemic therapy in la/mUC pts, potentially leading to underutilization of treatments

Insightful findings on real-world decision-making

meetings.asco.org/abstracts-pres…

⚡️ On European Urology - Cabozantinib + nivolumab shows promising results in non–clear cell renal cell carcinoma. With a 48% response rate and median overall survival of 28 months, this combination offers a potential new treatment option. No new safety concerns were observed.

Renal cancer highlights #ASCO24 KIM1 biomarker data (blood) stands out. KIM1 (TIM1-4 family) ⬆️ in kidney injury and is immune suppressive(Treg), Already used for nephrotox. Robert Motzer MD presented compelling data form adjuvant ipi/nivo #AACR24 . A 2nd +ve study would be meaningful?

We all always say that age is just a number, but it seems that when push comes to shove, those of us who treat patients with #bladdercancer do take into account the patient's age as an important parameter to take into account. Great pieco of work Shilpa Gupta!!!!!
Warming up for

💡La II Jornada Biomarcadores llega el 28 de mayo. Descubre cómo la #IA está redefiniendo el futuro de la medicina

📍Centro de Estudios Universitarios, Madrid
⏰ 16:00h – 19:00h
 
¡Regístrate aquí! 👉🏼 bit.ly/3ysDWYN

#JornadaBiomarcadores #estudioDipcan #oncología

Así es DIPCAN, el proyecto que busca un enfoque personalizado para combatir el cáncer en España

Leer más ➡️ atres.red/m09ae2 #NovaMás

Del 25 al 31 de mayo tiene lugar la Semana Europea contra el Cáncer. ¿Su objetivo? Sensibilizar sobre la prevención del cáncer, el acceso al tratamiento y el apoyo a las personas que sobreviven.

#SemanaEuropeaContraElCáncer #estudioDipcan #cáncer

⚡️ Out on European Urology - Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer

#BladderCancer Kent Mouw joaquim bellmunt Will Anderson

europeanurology.com/article/S0302-…

Ab#4566 ASCO #ASCO24 by joaquim bellmunt 👉tinyurl.com/yc4bvw74👉In JAVELIN Bladder 100 Ph3 trial of avelumab maintenance vs. supportive care in pts w/ low tumor burden #bladdercancer 👉⬆️long terms efficacy and manageable AEs 👇Shilpa Gupta OncoAlert UroToday.com Bladder Cancer Advocacy Network

Just in👉Our official ASCO #ASCODailyNews Podcast highlighting some GU abstracts from #ASCO24 👉 you can listen or read the transcript 👉Open access link to all across the world 👉 brnw.ch/21wK9q4 OncoAlert UroToday.com KidneyCAN PCF Science Bladder Cancer Advocacy Network

Con motivo de la Semana de la Lucha contra el Cáncer, hablamos de la importancia de la detección temprana del #CáncerDeVejiga junto al Enrique Grande y Laurent G, paciente de esta patología, quien cuenta el síntoma que le llevó al médico: bit.ly/4atqf9m.

⁦MD Anderson Madrid⁩ antena3.com/novamas/vida/a…

💊FOLFIRI vs. CapTem in the second line after platinum/etoposid for NECs
SENECA study
EORTC

✅The two regimens showed comparable activity
➡️GEP and lung NECs
➡️12 weeks-Disease Control Rate
39.1% vs 28%
➡️12 mo OS
28.4% vs 32.4%
➡️FOLFIRI: neutropenia, anemia
➡️CapTem:

Who else but ASCO
Can’t wait to see our amazing friends
So Looking forward to #ASCO24

Tom Powles Enrique Grande ylt Innovative trials like DISCUS are crucial. Excited to see the impact of 3 chemo cycles! #ASCO24

The DISCUS trial (3 vs 6 cycles of chemo then avelumab) needs 50 more pts for its initial readout. An investigator led study in 🇬🇧 🇫🇷 🇪🇸 Enrique Grande ylt with novel endpoints (ctDNA/wearable devices etc).Will cropping chemo help?Will 3 cycles have a role if +ve? #ASCO24

Dear Colleagues,
The OncoAlert 🚨Network Presents OUR Picks of
TOP 🔟Abstracts to be Presented at #ASCO24 for #KidneyCancer & #BladderCancer

This List Curated by:
#OncoAlertAF Leads : Emre Yekedüz 🇺🇸 Dra. María Natalia Gandur Quiroga 🇦🇷 Gil Morgan, MD 🇺🇸
Distinguished faculty Toni Choueiri, MD 🇺🇸